GoAI
Get started
P3 Health Partners Inc. logo

P3 Health Partners Inc.

PIII

NASDAQHealthcareMedical - Care Facilities

Open in GoAI

Regular session

$10.32

+$0.01 · +0.10%

Aug 24, 11:03 AM ET

PIII company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

42

Fair Value

Momentum

55

Neutral

Sentiment

59

Mixed

Risk resilience

33

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. The company operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
Aric Coffman
Listed since
Apr 6, 2021
Employees
320

Market position

Day range

Current $10.32

52-week range

Current $10.32

Open
$10.205
Previous close
$10.31
Volume
4.43K
0× average
Average volume
1.29M
Average daily volume
Market cap
33.81M USD
Beta
1.64
Market reference 1
50-day average
$10.8175
-4.60% below average
200-day average
$6.1734
+67.17% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
271.28M USD
P/E (TTM)
-0.31×
P/B (TTM)
0.48×
P/S (TTM)
0.02×
EV / EBITDA
-1.49×
Earnings yield
-1296.79%
Free cash flow yield
-799.72%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
31.65%
Operating margin
-9.89%
Net margin
-6.55%
Return on equity
95.31%
Return on assets
-22.53%
Return on invested capital
-172.80%

Financial health

Debt / equity
1.8×
Current ratio
0.24×
Altman Z-score
-0.27
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends125%25%-74%-174%Gross margin, FY2021: -4.82%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: -9.89%Operating margin, FY2021: -29.49%Operating margin, FY2022: -148.73%Operating margin, FY2023: -13.26%Operating margin, FY2024: -20.83%Operating margin, FY2025: -18.53%Net margin, FY2021: -24.55%Net margin, FY2022: -25.74%Net margin, FY2023: -4.56%Net margin, FY2024: -9.05%Net margin, FY2025: -10.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -4.82%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 -9.89%. Operating margin FY2021 -29.49%. Operating margin FY2022 -148.73%. Operating margin FY2023 -13.26%. Operating margin FY2024 -20.83%. Operating margin FY2025 -18.53%. Net margin FY2021 -24.55%. Net margin FY2022 -25.74%. Net margin FY2023 -4.56%. Net margin FY2024 -9.05%. Net margin FY2025 -10.14%.

Income trends

Revenue

1.46B USD-2.76%

Operating income

−270.3M USD+13.53%

Net income

−147.95M USD-8.91%
Income trends across reported periods1.81B USD582.04M USD−642.5M USD−1.87B USDRevenue, FY2021: 637.36M USDRevenue, FY2022: 1.05B USDRevenue, FY2023: 1.27B USDRevenue, FY2024: 1.5B USDRevenue, FY2025: 1.46B USDOperating income, FY2021: −187.95M USDOperating income, FY2022: −1.56B USDOperating income, FY2023: −167.93M USDOperating income, FY2024: −312.6M USDOperating income, FY2025: −270.3M USDNet income, FY2021: −156.48M USDNet income, FY2022: −270.13M USDNet income, FY2023: −57.77M USDNet income, FY2024: −135.85M USDNet income, FY2025: −147.95M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 637.36M USD. Revenue FY2022 1.05B USD. Revenue FY2023 1.27B USD. Revenue FY2024 1.5B USD. Revenue FY2025 1.46B USD. Operating income FY2021 −187.95M USD. Operating income FY2022 −1.56B USD. Operating income FY2023 −167.93M USD. Operating income FY2024 −312.6M USD. Operating income FY2025 −270.3M USD. Net income FY2021 −156.48M USD. Net income FY2022 −270.13M USD. Net income FY2023 −57.77M USD. Net income FY2024 −135.85M USD. Net income FY2025 −147.95M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.46B USD1.5B USD1.27B USD1.05B USD637.36M USD
Cost of goods sold1.6B USD———668.07M USD
Gross profit−144.32M USD1.5B USD1.27B USD1.05B USD−30.7M USD
Selling, general, and administrative107.23M USD113.93M USD125.6M USD162.38M USD119.41M USD
Operating expenses125.98M USD1.81B USD1.43B USD2.61B USD157.24M USD
Interest expense55.03M USD22.17M USD15.99M USD11.4M USD10.68M USD
Depreciation and amortization84.16M USD86.06M USD86.68M USD87.29M USD8.72M USD
Operating income−270.3M USD−312.6M USD−167.93M USD−1.56B USD−187.95M USD
Net income−147.95M USD−135.85M USD−57.77M USD−270.13M USD−156.48M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-119.91%
11 comparable reports
Latest EPS result
-0.63
Estimate -1.89 · Beat by 66.67%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.19-6.84-15.86-24.89Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -16, estimate -8.5, surprise -88.24%, Miss. Q2 2025, reported May 15, 2025: actual -6.28, estimate -5, surprise -25.60%, Miss. Q3 2025, reported Aug 14, 2025: actual -6.23, estimate -3.29, surprise -89.36%, Miss. Q4 2025, reported Nov 14, 2025: actual -9.67, estimate -5.29, surprise -82.71%, Miss. Q1 2026, reported Mar 26, 2026: actual -23.02, estimate -8.06, surprise -185.49%, Miss. Q2 2026, reported May 14, 2026: actual 0.32, estimate -4.85, surprise +106.60%, Beat. Q3 2026, reported Aug 10, 2026: actual -0.63, estimate -1.89, surprise +66.67%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -4.79, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates407.11M381.16M355.2M329.25MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 370.69M USD, estimate 378.88M USD, surprise -2.16%, Miss. Q2 2025, reported May 15, 2025: actual 373.23M USD, estimate 349.82M USD, surprise +6.69%, Beat. Q3 2025, reported Aug 14, 2025: actual 355.79M USD, estimate 344.91M USD, surprise +3.15%, Beat. Q4 2025, reported Nov 14, 2025: actual 345.25M USD, estimate 346.64M USD, surprise -0.40%, Miss. Q1 2026, reported Mar 26, 2026: actual 384.81M USD, estimate 353.68M USD, surprise +8.80%, Beat. Q2 2026, reported May 14, 2026: actual 386.39M USD, estimate 391.45M USD, surprise -1.29%, Miss. Q3 2026, reported Aug 10, 2026: actual 386.38M USD, estimate 377.8M USD, surprise +2.27%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 384.9M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.50

79.26% upside
Past 12 months12-month forecastHigh $23.00Average $18.50Low $14.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy250%
Hold250%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
BTIGdowngradeBuyNeutral

PIII news

marketbeat.com

P3 Health Partners Q2 Earnings Call Highlights

P3 Health Partners NASDAQ: PIII reported second-quarter adjusted EBITDA of $54 million and raised its full-year 2026 outlook, while noting that the quarterly result included $45 million of favorable payer settlements and…

Read source
seekingalpha.com

P3 Health Partners Inc. (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners Inc. (PIII) Q2 2026 Earnings Call Transcript

Read source
businesswire.com

P3 Health Partners Announces Second Quarter 2026 Results

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the…

Read source
businesswire.com

P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to…

Read source

PIII peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding PIII

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
278.76K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.26-0.26%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
127.53K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.91-0.66%

Continue in GoAI

Research PIII

research.disclaimer